Aerosol Drug Delivery Devices Market To Hit USD 80 Billion By 2032 – SNS Insider

(MENAFN- GlobeNewsWire - Nasdaq) The rising prevalence of respiratory diseases and technological advancements drive significant market growth.

Pune, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Aerosol Drug Delivery Devices Market Size & Growth Analysis:

According to SNS Insider, the Aerosol Drug Delivery Devices Market size was valued at approximately USD 26.40 billion in 2023, is anticipated to reach over USD 80.43 billion by 2032, reflecting a robust CAGR of 13.19% during the forecast period from 2024 to 2032. This substantial growth is primarily attributed to the increasing incidence of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD), coupled with continuous technological innovations in inhalation devices.

The increase in respiratory diseases has increased the need for effective and convenient drug delivery systems. Technology improvements in aerosol drug delivery technologies, such as smart inhalers and green propellants, have greatly improved patient compliance and efficacy. Additionally, the increased awareness of the advantages of inhalation therapy and the movement toward home-based healthcare solutions are further driving the growth of the market.

Get a Sample Report of Aerosol Drug Delivery Devices Market@

Key Industry Players operating in the Aerosol Drug Delivery Devices Market include:

• AptarGroup, Inc. - Aptar Pharma Inhalation Devices (such as Dry Powder Inhalers)
• Koninklijke Philips N.V. - Philips Respironics Inhalers (e.g., InnoSpire)
• AstraZeneca - Symbicort (MDI for asthma/COPD)
• Novartis AG - Breztri Aerosphere (MDI for COPD)
• Sanofi - Dupixent (Inhaler for asthma treatment)
• OMRON Corporation - OMRON CompAir (nebulizer systems)
• Medline Industries, LP. - Medline Nebulizer Kits
• GF Health Products, Inc. - GF Nebulizer Kits
• DRIVE MEDICAL GMBH & CO. KG - Drive Nebulizer
• Teva Pharmaceutical Industries Ltd. - ProAir HFA (MDI for asthma)
• Aerogen (Stamford Devices Limited Group) - Aerogen Ultra (nebulizer)
• Sensirion AG - Sensirion Inhalation Sensors
• PARI Respiratory Equipment, Inc . - PARI LC Plus Nebulizer
• Catalent, Inc. - Inhalation Solutions (for drug delivery)
• Pfizer Inc. - Ventolin HFA (MDI for asthma)
• Beurer GmbH - Beurer Nebulizer Systems

Aerosol Drug Delivery Devices Market Report Scope

Report Attributes	Details
Market Size in 2023	US$ 26.4 billion
Market Size by 2032	US$ 80.43 billion
CAGR	CAGR of 13.19% From 2024 to 2032
Base Year	2023
Forecast Period	2024-2032
Historical Data	2020-2022
Key Regional Coverage	North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)
Key Growth Drivers	The growth of the Aerosol Drug Delivery Devices market is primarily driven by the increasing prevalence of chronic respiratory diseases such as asthma and COPD.

Segment Analysis

By Type:

In 2023, inhalers were the leading segment, accounting for 86.3% of the overall revenue. Their success is due to their convenience, ease of administration, and quick onset of action, which makes them the first choice for treating chronic respiratory diseases. The most rapidly growing segment in this category is smart inhalers, which combine digital technology to track usage patterns and improve patient compliance. The growing uptake of these connected devices is poised to fuel huge growth in the inhaler category.

By Application:

COPD held the highest revenue share in the aerosol drug delivery devices market in 2023. The prevalence of COPD, particularly among the elderly population, is high and requires efficient and prompt treatment, thus driving the demand for aerosol drug delivery devices. Asthma management devices are expected to be the fastest-growing segment due to the increasing prevalence of asthma worldwide and the introduction of sophisticated inhalation therapies specific to asthma patients.

By Distribution Channel:

In 2023, institutional pharmacies held the largest market share in aerosol drug delivery device distribution. This is because institutional pharmacies have bulk purchasing power and direct supply chain relationships with healthcare providers. Online pharmacies are expected to be the fastest-growing distribution channel, as the convenience of online ordering and home delivery services gains popularity among patients, particularly in the post-pandemic period.

For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@

Aerosol Drug Delivery Devices Market Segmentation

By Type

• Nebulizers
  • Jet
  • Mesh
  • Active
  • Passive
  • Ultrasonic
• Inhaler
  • Pressurized Metered-Dose Inhaler (pMDI)
  • Dry-Powder Inhaler (DPI)

By Application

• COPD
• Asthma
• Cystic Fibrosis
• Other (Pulmonary Arterial Hypertension (PAH), etc.)

By Distribution

• Retail Pharmacies
• Online Pharmacies
• Institutional Pharmacies

Regional Insights

North America dominated the aerosol drug delivery devices market in 2023, due to sophisticated healthcare infrastructure, high level of awareness, and great investment in research and development. The Asia-Pacific region is expected to grow at the highest rate during the forecast period due to rising expenditure on healthcare, growing incidence of respiratory disorders, and increased use of advanced medical technologies in emerging economies.

Recent Developments

January 2025: Aerogen planned to invest around USD 308.5 million to increase its operations in Ireland, to improve its production and development capacity in aerosol drug delivery solutions.

October 2024: Aero Pump entered a collaboration with Resyca to market an ultra-soft nasal pump spray, aiming to enhance nasal drug delivery through targeted and efficient administration.

Statistical Insights and Trends

• Global incidence of COPD and asthma has been increasing, with millions being afflicted globally, highlighting the growing need for efficient aerosol drug delivery devices.
• North America had the highest prescription rates of aerosol drug delivery devices due to advanced healthcare infrastructures and high patient awareness.
• European government healthcare expenditure on respiratory care comprised around 15% of the overall healthcare budget, demonstrating huge investment in treating respiratory disorders.
• The rate of adoption of smart inhalers with digital monitoring capabilities grew by 25% worldwide, reflecting a trend towards the use of technology for better patient adherence and outcomes.

Buy a Single-User PDF of Aerosol Drug Delivery Devices Market Analysis & Outlook Report 2024-2032@

Table of Contents – Major Key Points

1. Introduction

2. Executive Summary

3. Research Methodology

4. Market Dynamics Impact Analysis

5. Statistical Insights and Trends Reporting

5.1 Device Adoption Rates and Trends (2023)

5.2 Regulatory Approvals and Market Penetration (2020-2023)

5.3 Healthcare Expenditure and Reimbursement Patterns (2023)

6. Competitive Landscape

7. Aerosol Drug Delivery Devices Market by Type

8. Aerosol Drug Delivery Devices Market by Application

9. Aerosol Drug Delivery Devices Market by Distribution

10. Regional Analysis

11. Company Profiles

12. Use Cases and Best Practices

13. Conclusion

Access Complete Report Details of Aerosol Drug Delivery Devices Market Analysis & Outlook 2024-2032@

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

MENAFN28022025004107003653ID1109262163